Naxitamab trial for children with treatment-resistant Ewing sarcoma
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial studies naxitamab (a targeted antibody) in children and young adults whose Ewing sarcoma has come back or kept growing despite prior treatment. You may be eligible if the tumor shows a target called GD2 and if your heart, lungs, and past treatment recovery meet safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 2 to 21 years
- Your diagnosis is Ewing sarcoma in bone or soft tissue confirmed by pathology
- Your prior Ewing sarcoma has progressed or recurred after at least one treatment
- Your tumor test is GD2-positive (a special lab stain on an existing biopsy sample)
- You must be at least 12 weeks expected survival and have recovered enough from prior treatments
- You cannot have had a previous anti-GD2 antibody treatment (like similar targeted drugs)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
This trial tests new drugs for young people with Ewing sarcoma or similar sarcomas that have come back or not responded to standard treatment. The goal is to see if these drugs can shrink or control the cancer.
This trial tests an experimental drug, KC1036, for adolescents with advanced Ewing sarcoma that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow the cancer.
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.